ArticleDiscover oncology2025
Shared hub genes in membranous nephropathy and kidney renal clear cell carcinoma: investigating molecular overlap and tumor progression.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMembranous nephropathy (MN) and kidney renal clear cell carcinoma (KIRC) are distinct kidney diseases with potential shared molecular mechanisms. Identifying common biomarkers may improve our understanding of disease pathogenesis and provide novel diagnostic and therapeutic targets.
methodsThe study primarily employed bioinformatics tools to analyze publicly available datasets to identify differentially expressed genes (DEGs) and hub genes in KIRC and MN. Functional interactions of the common DEGs were explored using protein-protein interaction (PPI) networks, and hub genes were further investigated through gene expression databases such as GSCA and UALCAN. Gene Set Enrichment Analysis (GSEA) was used to assess functional enrichment and tumor-driving potential. These bioinformatic results were then experimentally validated by knocking down FYN and LGALS8 in 786-O cells using siRNA, followed by RT-qPCR, protein analysis, and functional assays.
resultsThe study identified four hub genes (FYN, LGALS8, MAGI2, and WT1) in KIRC and MN, with FYN and LGALS8 upregulated and MAGI2 and WT1 downregulated. Bioinformatics validation showed excellent diagnostic performance and confirmed methylation and mutation patterns. Higher FYN and LGALS8 expression were linked to poorer survival. miRNA downregulation was validated in KIRC cell lines. Functional analysis revealed that FYN and LGALS8 promote KIRC progression through the ErbB signaling pathway, and knockdown experiments reduced cell proliferation, migration, and colony formation.
conclusionOur findings identify FYN, LGALS8, MAGI2, and WT1 as hub genes in KIRC, with potential diagnostic and prognostic value. These genes play significant roles in methylation, mutation, and immune regulation in KIRC. However, the results from the limited MN samples suggest possible roles of these genes in MN pathology, but further studies are required to fully assess the relevance of these findings to MN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.